Coming November 4: ASH publishes its abstracts and its oral and poster sessions. We’ll add the institutions presenting them as they become publicly available.

Servier at ASH 2026

Dec 12–15, 2026 New Orleans, LA ~30k attendees Website

Servier exhibits at Booth 2733 at ASH 2026 in New Orleans. Servier supports symposia on acute leukemias, from high-risk myeloid disease to lymphoblastic leukemia in younger patients. Its most specific topic is managing adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia, while another applies molecular findings to high-risk cases.

OrganizationASH 2026 Attendance
Servier
Suresnes, France
Large pharma3 exhibitor meeting rooms
French drugmaker governed by a non-profit foundation, with an oncology business focused on bringing new treatments to patients.
Booth
Exhibiting at Booth 2733
Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm
Symposium
Fri Dec 11
11:00am–2:00pm
Decoding High-Risk AML: Applying Molecular Insights to Clinical Decision-Making
Using tests for isocitrate dehydrogenase and Flt3 mutations to guide targeted therapy choices in acute myeloid leukemia.
Leukemias
Symposium
Fri Dec 11
7:00pm–10:00pm
Overcoming the Challenges of Managing Adolescents and Young Adults With Ph-Negative Acute Lymphoblastic Leukemia
Pediatric-style regimens, asparaginase, immunotherapy, and CAR-T for teens and young adults with acute lymphoblastic leukemia, plus their psychosocial needs.
Leukemias

Explore the full ASH 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in New Orleans. Leave your work email and we’ll be in touch.

Privacy

Download the full ASH 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Servier

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction